Fig. 1
From: Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
Detectability of CTCs and cfDNA in multiple myeloma. a Comparison of copy ratios between cfDNA ULP-WGS and CTC ULP-WGS from same MM patients. Amplification (red), deletion (green), and copy neutral (blue) are indicated. b Comparison of tumor fraction of matched cfDNA and CTC samples as determined via ULP-WGS and ichorCNA. Dashed line indicates 10% tumor fraction. Percentage of patients with ≥10% tumor fraction for cfDNA only (blue), CTC only (green), and cfDNA or CTC (purple) is indicated. Pearson correlation coefficient was calculated between the tumor fraction in cfDNA and CTC (Pearson correlation = 0.081; p-value = 0.680). c ULP-WGS tumor fraction estimates for 70 cfDNA samples and 39 enriched CTC samples from newly diagnosed MM and relapse patients; 76%, 41%, and 24% of cfDNA samples had ≥0.03, 0.05, and 0.1 tumor fractions, respectively (blue); 100%, 62%, and 31% of CTC samples had ≥0.03, 0.05, and 0.1 tumor fractions, respectively (green). d ULP-WGS tumor fraction estimates for 107 cfDNA samples and 56 CTC samples from MGUS, SMM, MM, and relapse patients; 58%, 28%, and 17% of cfDNA samples had ≥0.03, 0.05, and 0.1 tumor fractions, respectively (blue); 96%, 50%, and 21% of CTC samples had ≥0.03, 0.05, and 0.1 tumor fractions, respectively (green)
